Skip to content

Study · Animal study (in vivo) · rat · 2004

3 results

[The effect of ladasten on the activity of cAMP-dependent protein kinases and the phosphorylation of proteins in brain cells of rats].

Vakhitova IuV, Salimgareeva MKh, Seredenin SB

Eksperimental'naia i klinicheskaia farmakologiia1 May 2004Cited by 1 (Europe PMC)

PMID15341058 (opens in a new tab)PepBankPUB-15341058
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In rat brain, ladasten increased PKA activity during the initial drug-action period.

    In plain wordsIn rats, ladasten increased brain PKA activity during its initial action.

    Peptide
    Bromantane
    Outcome
    IncreasePKA activity
    Study

    ratn: not reported in source

    Rat brain soluble protein fraction
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    50 mg/kg · 1-12 hAs given in this study (rat).

    Source sentences

    Summary
    In this stage, ladasten increased the PKA activity, and the level of phosphorylation of one isoform of the main protein myelin (14 kD) and of the proteolipid protein (30 kD).
    2 context sentences
    Summary · context
    The effect of ladasten (50 mg/kg) on the activity of cAMP-dependent protein kinases (represented by protein kinase A (PKA)) in the soluble protein fraction of rat brain was studied.
    Summary · context
    Changes in the PKA activity were monitored in the initial period of drug action (1-12 h).
  2. 02AnimalAnimal study (in vivo)Mechanism

    In rat brain, ladasten increased phosphorylation of a myelin protein isoform.

    In plain wordsIn rats, ladasten increased phosphorylation of a brain myelin protein isoform.

    Peptide
    Bromantane
    Outcome
    IncreaseMyelin protein isoform phosphorylation
    Study

    ratn: not reported in source

    Rat brain soluble protein fraction
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    50 mg/kg · 1-12 hAs given in this study (rat).

    Source sentences

    Summary
    In this stage, ladasten increased the PKA activity, and the level of phosphorylation of one isoform of the main protein myelin (14 kD) and of the proteolipid protein (30 kD).
    2 context sentences
    Summary · context
    The effect of ladasten (50 mg/kg) on the activity of cAMP-dependent protein kinases (represented by protein kinase A (PKA)) in the soluble protein fraction of rat brain was studied.
    Summary · context
    Changes in the PKA activity were monitored in the initial period of drug action (1-12 h).
  3. 03AnimalAnimal study (in vivo)Mechanism

    In rat brain, ladasten increased proteolipid protein phosphorylation.

    In plain wordsIn rats, ladasten increased phosphorylation of brain proteolipid protein.

    Peptide
    Bromantane
    Outcome
    IncreaseProteolipid protein phosphorylation
    Study

    ratn: not reported in source

    Rat brain soluble protein fraction
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    50 mg/kg · 1-12 hAs given in this study (rat).

    Source sentences

    Summary
    In this stage, ladasten increased the PKA activity, and the level of phosphorylation of one isoform of the main protein myelin (14 kD) and of the proteolipid protein (30 kD).
    2 context sentences
    Summary · context
    The effect of ladasten (50 mg/kg) on the activity of cAMP-dependent protein kinases (represented by protein kinase A (PKA)) in the soluble protein fraction of rat brain was studied.
    Summary · context
    Changes in the PKA activity were monitored in the initial period of drug action (1-12 h).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.